Gennex Laboratories Ltd (GENNEX)

Loading page…

Gennex Laboratories Ltd (GENNEX) · mywealthgrid

About

Gennex Laboratories is a mid-sized standalone pharmaceutical company with a market cap of ₹291 Cr. Quarterly revenues run ₹21–25 Cr (₹14 Cr in earlier quarters). The company operates with minimal debt (D/E 0.05), though institutional investors (FII, DII) hold zero stakes.

Face value: ₹1

Market cap

₹238 Cr

P/E

12.9×

P/B

1.1×

Dividend yield

ROE

ROCE

11.3%

Debt / equity

0.16

OPM

12.6%

EPS (TTM)

₹0.8

Book value

₹9.2

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Margin collapse: OPM fell from 13.85% (Dec 2024) to 0.3% (Mar 2025), while revenue stayed flat at ₹23 Cr. Verify the cause and durability of recovery. - Revenue swings of 40–80% quarter-to-quarter suggest either seasonal/project-lumpy sales or operational inconsistency; verify the sales model. - Stock down 2.44% over 12 months and traded ₹7.13–₹17.02 (138% range), indicating volatility or investor uncertainty. - Zero institutional holding (FII 0%, DII 0%) leaves the stock without analyst coverage or capital-raise runway.

Generated analysis · source review pending

Growth drivers

Revenue grew 79% from ₹14.15 Cr (Jun 2023) to ₹25.28 Cr (Dec 2024); if this trajectory resumes after the Mar 2025 dip, volume growth could expand absolute profit. - Low D/E ratio (0.05) provides balance sheet capacity to fund capex or M&A to scale production; verify if expansion is planned. - OPM previously held 13–27% range; recovery to 13–15% baseline would double net profit at current revenue, improving ROE above current 10.15%.

Generated analysis · source review pending

2,177 historical price candles were omitted because the exchange source has not been verified.

₹9.8-2.8%1Y

Quick read

rule-based

Pros

+Profit CAGR of 35.6% over the last 5 years
+Revenue CAGR of 23.7% over the last 5 years

Cons

−Low promoter holding of 23.6%

Research score

Structured signal from quality, growth, valuation and momentum.

75/100

Business quality: 39
Growth: 100
Valuation: 85

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	60	61	66	87	138	173
COGS	36	38	40	49	97	129
Gross profit	24	23	26	38	41	44
	17	18	21	21	24	22
	7	5	5	17	17	22
OPM %	11%	8.8%	7.2%	19.6%	12%	12.6%
Depreciation	1	1	1	2	2	3
Interest	1	1	1	3	4	4
	0	1	4	5	10	8
Profit before tax	5	5	6	16	21	23
Tax	1	1	1	3	3	2
Tax %	20.2%	23%	22.8%	20.1%	15.3%	9.7%
	4	4	5	13	18	21
PAT margin %	6.8%	6.4%	7.5%	15.2%	13.1%	12.2%
EPS (₹)	—	—	0.4	—	—	0.8
EPS adjusted (₹)	0.3	0.3	0.3	0.6	0.8	0.8
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	13	13	13	18	23	23	24
Reserves	—	27	31	—	148	164	198
Minority interest	—	—	0	—	—	0	10
	—	7	10	—	6	10	36
	—	12	14	—	54	59	80
Total equity & liabilities	—	59	68	—	230	256	349
	15	14	14	73	55	59	61
CWIP	—	—	—	—	12	15	13
Investments	—	7	7	—	0	0	0
	—	38	48	—	163	182	275
Total assets	—	59	68	—	230	256	349

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-1	7	24	-50	-11	-64
	-0	-1	-38	19	1	-5
	2	2	21	77	5	65
Net cash flow	0	7	6	46	-5	-3
Free cash flow	-2	6	-16	-50	-20	-76
CFO / Operating profit %	-22.1%	123.4%	505.8%	-294.2%	-65.2%	-291.4%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	40.1%	37.8%	39.2%	43.7%	29.6%	25.6%
EBITDA margin %	11%	8.8%	7.2%	19.6%	12%	12.6%
EBIT margin %	9.5%	7.5%	5.7%	16.9%	10.6%	11.1%
PAT margin %	6.8%	6.4%	7.5%	15.2%	13.1%	12.2%
Working capital
Receivable days	55	67	—	75	37	92
Inventory days	51	74	—	188	135	153
Payable days	61	74	—	113	49	58
NWC days	45	67	—	150	123	187
Leverage
Current ratio	1.98	1.95	—	4.02	4.06	3.66
Debt to EBITDA	1.13	1.88	—	0.34	0.62	1.65
Debt to equity	0.19	0.23	—	0.03	0.05	0.16
Interest coverage	8.3	6.8	5.7	6.4	6.9	6.5
Asset turnover	1.01	0.9	—	0.38	0.54	0.5
Return ratios
Return on assets %	6.9%	5.8%	—	5.7%	7.1%	6%
Return on capital employed %	15.5%	14.3%	—	10.3%	12.5%	11.3%
Return on equity %	10.2%	8.9%	—	7.7%	9.7%	9.4%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	23.6%	23.6%	18.42%	18.42%	18.42%	18.42%	18.42%	19.83%	23.62%	23.62%	23.63%	23.63%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	76.4%	76.4%	81.58%	81.58%	81.58%	81.58%	81.58%	80.17%	76.38%	76.38%	76.37%	76.37%
No. of shareholders	—	—	—	—	—	—	—	—	90,320	86,306	84,133	82,886

Promoter holding up 0.03 percentage points since Sep 2023.

74 deals · 28 Dec 2021 – 22 May 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
22 May 2026	ANUPRIYA CONSULTANTS PVT LTD	Bulk	BSE	Buy	12,75,000	₹11.92	₹1.52 Cr
22 May 2026	ANUPRIYA CONSULTANTS PVT LTD	Bulk	BSE	Sell	6,25,000	₹12.30	₹0.77 Cr
19 May 2026	ANUPRIYA CONSULTANTS PVT LTD	Bulk	BSE	Buy	19,34,782	₹9.97	₹1.93 Cr
15 Oct 2025	DORITE TRACON PRIVATE LIMITED	Bulk	BSE	Buy	15,01,719	₹13.75	₹2.06 Cr
15 Oct 2025	KAMAL KUMAR DUGAR AND CO ( PROP : KAMAL KUMAR DUGAR)	Bulk	BSE	Sell	11,75,000	₹13.81	₹1.62 Cr
14 Oct 2025	NARANTAK DEALCOMM LIMITED	Bulk	BSE	Buy	20,00,000	₹13.37	₹2.67 Cr
30 Sept 2025	TROPICAL AGRO SYSTEM INDIA PRIVATE LIMITED	Bulk	BSE	Sell	17,00,000	₹11.01	₹1.87 Cr
12 Mar 2025	MARYADA BARTER PRIVATE LIMITED	Bulk	BSE	Buy	12,07,467	₹12.73	₹1.54 Cr
18 Oct 2024	KAMAL KUMAR DUGAR AND CO ( PROP : KAMAL KUMAR DUGAR)	Bulk	BSE	Sell	11,74,666	₹22.62	₹2.66 Cr
10 Oct 2024	L7 HITECH PRIVATE LIMITED	Bulk	BSE	Sell	24,52,005	₹22.87	₹5.61 Cr

1–10 of 74

1 / 8

Mr. ARIHANT BAIDExecutive Director-Chairperson-MD
Mr. DILIP RAJ SINGHVINon-Executive - Independent Director
Mr. AVASARALA RANGA RAO PANTULUNon-Executive - Non Independent Director
Mr. AMUDALA SREERAMULU NAGESWAR RAONon-Executive - Independent Director
Mr. SANDEEP KUMAR DAGANon-Executive - Non Independent Director
Ms. KHUSHBU KACHHAWANon-Executive - Independent Director
Mr. K V L N BhaswanthChief Operation Officer
Mr. Akkali Santosh KumarChief Financial Officer
Mr. Dinesh Kumar KejriwalCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Gennex Laboratories Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results14 Aug 2026

1

Face value ₹10 → ₹114 Dec 2009 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

16 announcementsExport CSV

1 Oct 2026, 2:23 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM

Loading announcements…

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	40.1%	37.8%	39.2%	43.7%	29.6%	25.6%
EBITDA margin %	11%	8.8%	7.2%	19.6%	12%	12.6%
EBIT margin %	9.5%	7.5%	5.7%	16.9%	10.6%	11.1%
PAT margin %	6.8%	6.4%	7.5%	15.2%	13.1%	12.2%
Working capital
Receivable days	55	67	—	75	37	92
Inventory days	51	74	—	188	135	153
Payable days	61	74	—	113	49	58
NWC days	45	67	—	150	123	187
Leverage
Current ratio	1.98	1.95	—	4.02	4.06	3.66
Debt to EBITDA	1.13	1.88	—	0.34	0.62	1.65
Debt to equity	0.19	0.23	—	0.03	0.05	0.16
Interest coverage	8.3	6.8	5.7	6.4	6.9	6.5
Asset turnover	1.01	0.9	—	0.38	0.54	0.5
Return ratios
Return on assets %	6.9%	5.8%	—	5.7%	7.1%	6%
Return on capital employed %	15.5%	14.3%	—	10.3%	12.5%	11.3%
Return on equity %	10.2%	8.9%	—	7.7%	9.7%	9.4%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Date	Category	Subject	Filing
1 Oct 2026, 2:23 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
30 Sept 2026, 6:29 pm	Company Update Change in Management	Announcement under Regulation 30 (LODR)-Change in Management	PDF
30 Sept 2026, 6:13 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
22 Sept 2026, 2:29 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
9 Sept 2026, 1:47 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
8 Sept 2026, 5:37 pm	Company Update General	Approval Of Additional Products From Drugs Control Administration, Government Of Andhra Pradesh For Our Subsidiary Company, Deccan Remedies Limited	PDF
8 Sept 2026, 3:01 pm	Others Reg. 34 (1) Annual Report	Reg. 34 (1) Annual Report.	PDF
4 Sept 2026, 5:40 pm	Corp. Action Book Closure	Intimation Of Book Closure For The Purpose Of 41St AGM Of Gennex Laboratories Limited	PDF

Gennex Laboratories Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

1

1

Announcements

1

1

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Gennex Laboratories Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Board meetings1

Stock splits1

Announcements

Board meetings1

Stock splits1

Ratio timeline

Not in the F&O segment

No fund holdings on record

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

1

1

1

1